



ASX / Media Release  
20 April 2017

## Specialised Therapeutics Australia to Support OncoSil™ Pancreatic Clinical Study Program

### Highlights

- Independent pharmaceutical company Specialised Therapeutics Australia (STA) to support OncoSil Medical global Pancreatic Cancer study
- STA to supply subsidised ABRAXANE® (nanoparticle albumin-bound paclitaxel) to Australian sites for clinical study
- ABRAXANE® is marketed in Australia by STA under license from Celgene Corporation
- Majority of patients recruited at five key Australian trial sites expected to be provided gemcitabine plus ABRAXANE® chemotherapy combination

**Sydney, Australia, 20 April 2017:** OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, will collaborate with independent biopharmaceutical company Specialised Therapeutics Australia (STA) to support the company's global clinical study program examining OncoSil Medical's proprietary technology in combination with different chemotherapy regimens.

Under the terms of the arrangement, STA has authorised a significantly-subsidised supply of ABRAXANE to be used by all Australian sites participating in the global study. STA markets ABRAXANE® in Australia & New Zealand exclusively under license from the Celgene Corporation.

Australian study participants will all receive OncoSil™ plus FOLFIRINOX, or OncoSil plus a gemcitabine/ABRAXANE combination chemotherapy treatment. It is expected that most Australian patients enrolled will receive the gemcitabine/ABRAXANE chemotherapy combination.

STA Chief Executive Officer Mr Carlo Montagner said he was pleased to collaborate with OncoSil on the global study and looked forward to potentially changing treatment paradigms for pancreatic cancer.

"Despite incremental advances, pancreatic cancer continues to have one of the lowest survival rates in oncology," he said "We look forward to seeing data from this important global study and hope it paves the way for new ways of treating this aggressive cancer." ABRAXANE was listed on the Australian Pharmaceutical Benefits Schedule for Australian patients with metastatic pancreatic cancer in 2014, following a pivotal Phase 3 study demonstrating that ABRAXANE plus gemcitabine significantly improved overall survival, progression free survival and response rates compared to gemcitabine alone.<sup>1</sup>

Commenting on support of the trial, OncoSil Chief Executive Officer, Daniel Kenny said:

“We are extremely pleased to receive the generous support of Specialised Therapeutics Australia for the Australian arm of our global pancreatic study, and are greatly encouraged by the interest our study continues to generate globally.”

- ENDS -

Company	Media
<b>Mr Daniel Kenny</b> CEO & Managing Director E: <a href="mailto:daniel.kenny@oncosil.com.au">daniel.kenny@oncosil.com.au</a> T: +61 2 9223 3344	<b>Ben Walsh</b> WE Buchan E: <a href="mailto:bwalsh@buchanwe.com.au">bwalsh@buchanwe.com.au</a> M: 0411 520 012

### About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch, subject to approval.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

### About Specialised Therapeutics Australia

Specialised Therapeutics Australia (STA) is an international biopharmaceutical company dedicated to working with leading biotechnology and pharmaceutical companies worldwide. The company's primary objective is to enable unrestricted access to breakthrough acute care therapies and genomic diagnostics to people with high unmet medical needs living in Australia, New Zealand and throughout South East Asia. The STA therapeutic portfolio and pipeline spans oncology, haematology, gene expression assays, ophthalmology and neurology, although is not restricted to these areas of therapeutic interest. STA also has interests emerging cardiology, respiratory, dermatology, endocrinology and central nervous system (CNS) technologies. For further information, please go to: [www.STAbiopharma.com](http://www.STAbiopharma.com)

### About ABRAXANE

Developed using the proprietary *nab*™ technology platform, ABRAXANE is a nanoparticle protein-bound chemotherapy agent. ABRAXANE combines paclitaxel with albumin, a naturally-occurring human protein,

which enhances delivery of paclitaxel to the tumour and also eliminates the need for solvents in the administration process. ABRAXANE is approved for the treatment of metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer. In Australia, ABRAXANE is currently listed on the PBS for the treatment of metastatic breast cancer, and metastatic pancreatic cancer (in combination with gemcitabine). ABRAXANE is not PBS listed for the indication of NSCLC. ABRAXANE is currently in various stages of investigation for the treatment of the following cancers: early stage pancreatic cancer, squamous and non-squamous NSCLC and expanded applications in breast cancer. BEFORE PRESCRIBING PLEASE CONSULT THE ABRAXANE PRODUCT INFORMATION AVAILABLE AT [www.STAbiopharma.com](http://www.STAbiopharma.com)

#### References:

1. Von Hoff DD et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013; 369 (18): 1691-703

**ABRAXANE® is a registered trademark of Celgene Corporation**

**ABRAXANE® is under license from Celgene Corporation and distributed by STA in Australia and New Zealand**

#### Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.